According to preclinical studies, using a potent nMAb cocktail targeting the angiotensin-converting enzyme 2 (ACE2) and broad-nMAbs targeting of conserved regions within Spike may be effective for the treatment and prevention of COVID-19 [60]. The gene discussed is ACE2; the disease is COVID-19.